M Uusitupa 10,18 , I Thorsdottir 1,2 and U Risé rus 8 BACKGROUND/OBJECTIVES: Few studies have used biomarkers of whole-grain intake to study its relation to glucose metabolism. We aimed to investigate the association between plasma alkylresorcinols (AR), a biomarker of whole-grain rye and wheat intake, and glucose metabolism in individuals with metabolic syndrome (MetS). SUBJECTS/METHODS: Participants were 30-65 years of age, with body mass index 27-40 kg/m 2 and had MetS without diabetes. Individuals were recruited through six centers in the Nordic countries and randomized to a healthy Nordic diet (ND, n ¼ 96), rich in whole-grain rye and wheat, or a control diet (n ¼ 70), for 18-24 weeks. In addition, associations between total plasma AR concentration and C17:0/C21:0 homolog ratio as an indication of the relative whole-grain rye intake, and glucose metabolism measures from oral glucose tolerance tests were investigated in pooled (ND þ control) regression analyses at 18/24 weeks. RESULTS: ND did not improve glucose metabolism compared with control diet, but the AR C17:0/C21:0 ratio was inversely associated with fasting insulin concentrations (P ¼ 0.002) and positively associated with the insulin sensitivity indices Matsuda ISI (P ¼ 0.026) and disposition index (P ¼ 0.022) in pooled analyses at 18/24 weeks, even after adjustment for confounders. The AR C17:0/C21:0 ratio was not significantly associated with insulin secretion indices. Total plasma AR concentration was not related to fasting plasma glucose or fasting insulin at 18/24 weeks. CONCLUSIONS: The AR C17:0/C21:0 ratio, an indicator of relative whole-grain rye intake, is associated with increased insulin sensitivity in a population with MetS.
INTRODUCTION
Whole-grain and cereal fiber consumption has been inversely associated with the risk of type 2 diabetes and insulin sensitivity in observational studies, [1] [2] [3] [4] [5] but findings have been inconsistent in intervention studies. [6] [7] [8] [9] [10] [11] A possible reason for the inconclusive results seen in intervention studies may be inadequate dietary compliance. Nutritional science relies on accurate dietary information to assess compliance to dietary interventions and to investigate diet-disease associations. However, most dietary assessment instruments rely to some extent on self-reporting, which is prone to measurement errors. 12, 13 The use of dietary biomarkers could be one way to improve the validity of dietary assessment in combination with, or as an alternative for, selfreports or as a tool for secondary analysis, where noncompliant individuals can be excluded on the basis of the biomarker measurements.
Alkylresorcinols (AR) have been proposed as biomarkers for whole-grain and bran intake of wheat and rye [14] [15] [16] and for cereal fiber intake in populations with a high intake of whole-grain wheat and rye. 17 AR are almost exclusively present in the outer parts of wheat and rye grains and not in refined white flour. 18, 19 Controlled whole-grain and bran intervention studies show that plasma AR concentration increases proportionally with AR and whole-grain intake 16, [20] [21] [22] [23] [24] and can be used as a biomarker of compliance to a whole-grain diet. 15, 25 Previously, we have demonstrated that AR are useful biomarkers for whole-grain wheat and rye intake as part of a healthy Nordic diet (ND). 26 Total plasma AR have been associated with lower body mass index 1 (BMI) in older adults, but no associations between AR and glucose metabolism were found. 27 The ratio of the AR homologs C17:0 and C21:0 differs between cereal species and can be used to differentiate between the whole-grain sources in food products. 19 The ratio of C17:0/C21:0 is typically 0.1 in common wheat and 1.0 in rye, and the relative intake of whole-grain rye and wheat is to some extent reflected by this ratio in plasma samples. 23 In the present study the aim was to investigate the association between plasma AR, as a biomarker for whole-grain wheat and rye intake, and glucose metabolism in a population with features of metabolic syndrome participating in a randomized dietary intervention. 28 Furthermore, the associations between the AR C17:0/C21:0 ratio, as a marker of relative whole-grain bran/rye intake, and glucose and insulin parameters were analyzed.
MATERIALS AND METHODS
The current study is part of the SYSDIET study, a randomized controlled multicenter parallel group study with balanced randomization (1:1) performed in six intervention centers (Kuopio and Oulu, Finland; Lund and Uppsala, Sweden; Aarhus, Denmark and Reykjavik, Iceland) examining the health effects of a ND in a population with metabolic syndrome. All local ethical committees approved the SYSDIET study protocol which followed the Helsinki declaration guidelines. Informed written consent was obtained from all participants. The study design, inclusion and exclusion criteria, study diets, the main measurements and analyses performed at each time point and main results have been previously reported in detail. 28 
Study participants
Participants in the study were primarily recruited through advertisement in newspapers, but also from previous clinical or epidemiological trials. In brief, the inclusion criteria were age 30-65 years, BMI 27-40 kg/m 2 and two diagnostic criteria for metabolic syndrome outlined by the International Diabetes Federation, 29 except type 2 diabetes.
Study design
Before randomization into the ND group and the control group, participants had a 1-month run-in period, during which all the participants followed their habitual diet. Owing to financial and logistic reasons, the study period was 18 weeks at four centers (Aarhus, Uppsala, Reykjavik and Oulu) and 24 weeks at two centers (Lund and Kuopio), where the intervention was initiated earlier. 28 The major visits to the study clinics were on week 0 (baseline), week 12 and 18/24 weeks.
The randomization was done by staff in each study center as described elsewhere. 28 The staff in all study centers was trained to perform measurements in a similar way and the quality management protocol was available for all of the staff members. The allowed weight change during the study was aimed to be o ± 4 kg.
Study diets
The study diets were isocaloric. Nordic nutrition recommendations formed the basis of the diet in the ND group and the mean nutrient intake in the Nordic countries formed the basis for the control diet. Participants in the ND group were, among other things, advised to consume X25% of total energy as whole grain, of which X50% was comprised of rye, barley and oat that included X6 slices/day of bread with X6 g fiber/100 g (one slice ¼ 30-40 g of bread). Participants in the control group were asked to consume X25% of energy as refined grain, of which X90% was made from wheat.
Key products were provided to the study participants in both groups. The individuals in the ND group received whole-grain products such as oats and barley, crisp breads, whole-grain wheat and rye breads. The individuals in the control group received low-fiber cereal products, for example breads with fiber content o6 g/100 g and ordinary pasta.
The participants met a clinical nutritionist or a dietitian at all study visits. The study participants kept dietary records regarding the intake of cereal products. These records were checked at each visit to the study center, including the visits when the groceries were delivered to the participants, that is at 1-2 weeks intervals, and the subjects also returned 4-day food records at baseline, week 12 and 18/24 weeks.
Biochemical measurements
Automated clinical chemistry analyzers and routine clinical chemistry methods were used to measure cholesterol, triglycerides and high-density lipoprotein cholesterol. The equipment and system reagents were from Siemens Healthcare Diagnostics (Tarrytown, NY, USA), Thermo Fisher Scientific (Vantaa, Finland), Roche Diagnostics GmbH (Mannheim, Germany) (in two laboratories), Toshiba (Tochigi, Japan), Abbott Laboratories (Irving, TX, USA), Ortho-Clinical Diagnostics and Johnson & Johnson (New Brunswick, NJ, USA). 28 Low-density lipoprotein cholesterol concentrations were calculated using Friedewald's formula (low-density lipoprotein ¼ total cholesterol À high-density lipoprotein cholesterol À (triglycerides/5)).
Two-hour oral glucose tolerance test
A 2-h oral glucose tolerance test was performed at baseline, week 12 and at 18/24 weeks. The subjects were instructed to fast for 12 h before the oral glucose tolerance test. Fasting samples for plasma glucose, plasma insulin and triglycerides were collected at time point 0, before the glucose solution was ingested. The subjects were asked to drink 75 g of D( þ ) -glucose anhydrous Ph.Eur and 1.6 g of citric acid dissolved in 300 ml water in o3 min. Blood samples for glucose and insulin analyses were collected 30 and 120 min after the glucose load. Analyses of plasma glucose were performed in local laboratories using standard operational procedures. Plasma insulin was analyzed at Aarhus University Hospital using the ELISA method from Dako Denmark A/S, Glostrup, Denmark, with a within-run and between-run CVo8% and o10%, respectively.
Analysis of AR
Blood samples analyzed for AR were collected at baseline, week 12 and 18/24. Determination of AR in plasma samples were made in collaboration with the HELGA-Centre at Department of Food Science, BioCenter at Swedish University of Agricultural Sciences. A gas chromatography mass spectrometry method was used to quantify AR homologs C17:0-C25:0 in 0.2 ml plasma samples, as described previously. 30 Quality control samples (n ¼ 4) were included in each batch to ensure appropriate within-and between-batch precision (CVo15%). Samples from each subject were analyzed within the same batch, and samples from different centers were allocated randomly between batches.
Data pooling and statistical analysis
All intervention centers entered their data into the Microsoft Office Excel 2007 (Windows) data form before pooling the data in a joint database maintained at VTT Technical Research Centre of Finland. Data was exported from the database and imported to SPSS (Statistical Package for the Social Sciences) for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA) for statistical analysis. Level of significance in all analyses was set at Po0.05.
Normality of variables was checked by inspection and by using the Kolmogorov-Smirnov test. Values are described as means and s.d. if normally distributed or as medians and interquartile range if not normally distributed. Independent sample t-tests or Mann-Whitney's U-test were used to compare data between groups. When comparing values at baseline to week 18/24 values, paired samples t-test or the Wilcoxon signed-rank test was used.
From data of the oral glucose tolerance test insulinogenic index (IGI), the ratio of the 30-min areas under the curve for insulin and glucose (InsAUC0-30/GluAUC0-30) and Stumvoll was calculated for evaluation of early-phase insulin secretion (IGI ¼ (insulin 30 min À insulin 0 min)/(glucose 30 min À glucose 0 min) and Stumvoll ¼ 1283 þ 1.829 Â insulin 30 min (pmol/l) À 138.7 Â glucose 30 min (mmol/l) þ 3.772 Â insulin 0 min (pmol/l)). IGI at 120 min (IGI 120) was calculated for late-phase insulin secretion (IGI 120 ¼ (insulin 120 min À insulin 0 min)/(glucose 120 min À glucose 0 min)). Matsuda insulin sensitivity index (ISI) and disposition index (DI) were calculated for evaluation of insulin sensitivity (Matsuda ISI ¼ (10 000/ O((glucose 0 min Â insulin 0 min) Â (arithmetic mean of glucose at 0, 30 and 120 min Â arithmetic mean of insulin at 0, 30 and 120 min))) 31 and DI ¼ Matsuda ISI Â IGI).
Secondary analyses were performed with data from the ND and control groups combined and associations between total AR and the AR C17:0/C21:0 ratio at 18/24 weeks, and various glucose and insulin outcomes were analyzed. As the distributions were skewed, logtransformation was performed on dependent variables for linear regression to better approximate normal distribution. Linear regressions for fasting plasma glucose, insulin, Matsuda, DI and IGI was calculated, with AR C17:0/C21:0 ratio, baseline value for the dependent variable, age, gender, BMI and smoking as factors in model 1. As rye often contains more AR compared with wheat, total plasma AR was added as a variable to model 2, in addition to the variables in model 1, to prevent confounding of high AR content. Spearman's r was calculated to estimate the correlation between AR C17:0/C21:0 ratio and total plasma AR.
RESULTS
In total, 201 individuals started the intervention; 104 in the ND group and 97 in the control group. Individuals completing the trial were 96 in the ND group (92%) and 70 in the control group (72%). There was no difference in basic baseline characteristics between dropouts and those who completed the study (data not shown). Blood samples for AR analysis at week 0 and week 18/24 were obtained from 158 participants.
Consistent with the isocaloric study design there was no change in total energy intake during the study and energy intake was not different between the groups. Hence, body weight remained constant during the intervention in both groups. The mean age of the participants was 54.5±8.2 years, body weight 91.2±13.5 kg, BMI 31.7 ± 3.2 kg/m 2 and waist circumference 104.3 ± 9.7 cm. Sixty-three percent of the participants were classified as obese (BMIX30 kg/m 2 ) and 37% as overweight (BMI 25-29.99 kg/m 2 ) at baseline. Ninety-eight individuals (59%) had fasting plasma glucose X5.6 mmol/l at baseline and 161 (97%) had metabolic syndrome. There were no differences in baseline characteristics between the ND and control groups. 28 Both total plasma AR concentration and the ratio of C17:0/C21:0 were significantly higher in the ND group compared with the control group at 18/24 weeks (Table 1) . Fasting plasma glucose was 5.7±0.9 mmol/l in both groups at baseline and did not change significantly during the intervention period. There were no significant differences between the ND group and control group in concentrations of fasting glucose, 2 h glucose (results described elsewhere 28 ), fasting insulin, 2 h insulin, other calculated glucose metabolism parameters or the changes in these values during the intervention (Table 1) .
All participants (both ND and control groups) were combined for secondary analyses on the associations between AR and glucose metabolism. Total plasma AR concentration at 18/24 weeks was not significantly correlated with concentrations of fasting plasma glucose (P ¼ 0.51) or insulin (P ¼ 0.57) when adjusted for baseline value of the dependent variable, age, gender, BMI and smoking. Combining the data from both weeks 12 and 18/24 did not change the results. Interestingly, the AR ratio C17:0/C21:0, reflecting the proportion of whole-grain rye to wholegrain rye þ whole-grain wheat, was inversely associated with fasting insulin concentrations when adjusted for baseline value of insulin, age, gender, BMI and smoking (model 1, P ¼ 0.016) and also when total plasma AR was added to the regression model (model 2, P ¼ 0.011) ( Table 2) . Total plasma AR and the AR C17:0/C21:0 ratio was weakly correlated (r ¼ 0.20, P ¼ 0.012). The AR C17:0/C21:0 ratio was also positively associated with the insulin sensitivity indices Matsuda ISI (P ¼ 0.005 and P ¼ 0.004 for model 1 and 2, respectively) and DI (P ¼ 0.022 and P ¼ 0.023 for model 1 and 2, respectively) ( Table 2 ). The AR C17:0/C21:0 ratio was, however, not associated with fasting plasma glucose (P ¼ 0.12 and P ¼ 0.11 for model 1 and 2, respectively), or the indices for early and late insulin secretion, that is, IGI (P ¼ 0.54 and P ¼ 0.59 for model 1 and 2, respectively), InsAUC0-30/GluAUC0-30 (P ¼ 0.65 and P ¼ 0.54 for model 1 and 2, respectively), Stumvoll or IGI 120 (P ¼ 0.93 and P ¼ 0.99 for model 1 and 2, respectively) and IGI 120 (P ¼ 0.11 and P ¼ 0.12 for model 1 and 2, respectively).
DISCUSSION
In the present study, consuming a ND rich in whole-grain cereals for either 18 or 24 weeks did not improve glucose metabolism compared with a control diet. When values from both groups were pooled, no association between total plasma AR concentration and glucose metabolism parameters were observed.
There are conflicting findings from previous intervention studies evaluating the effects of whole-grain intake on glucose and insulin concentrations and calculated parameters of insulin sensitivity 8, 11, 27, 32 presumably owing to differences in the type, amount, structure and preparation of whole-grain products consumed 33 and different methodologies used for glucose and insulin analyses. 7 Poor compliance could also contribute to these diverse findings, although good adherence has been indicated in most studies using weighed food records. In a whole-grain intervention study by Kristensen et al. 9 the effects on body composition were clearer after excluding noncompliant subjects based on AR concentration, although food records indicated good compliance. Hence, without an objective measurement of compliance, such as biomarkers, it is difficult to rule out the possibility of low adherence to the intervention diet.
The most interesting results of the present study are the inverse associations between the AR C17:0/C21:0 ratio and fasting plasma insulin concentration and insulin sensitivity indices, Matsuda ISI and DI, that is, the higher the ratio the better was the insulin sensitivity. Matsuda ISI is the most commonly used index to illustrate peripheral insulin sensitivity, of mostly peripheral muscle tissue insulin sensitivity. 34 We also found an association between DI and AR C17:0/C21:0, which suggests that AR may also have a role with improvement of beta-cell function when the respective insulin sensitivity has been taken into account, as DI reflects insulin secretion but takes into account the insulin sensitivity effect. 34 Although the ratio of C17:0/C21:0 is B1.0 in rye, the ratio is somewhat lower in plasma samples, typically around 0.6-0.8 in fasting samples after a whole-grain rye intervention for 1-8 weeks. 21, 23 In populations where rye is not commonly consumed the ratios are generally lower and a ratio above 0.15 is usually indicative of some rye intake. 35 The ratio in free-living Swedish population, where rye consumption is appreciable, is 0.5. 36 The reason for lower ratio in plasma compared with what is observed in whole-grain bran/rye foods is likely due to faster metabolism of the AR homolog C17:0, 37, 38 but further insight into absorption and metabolism of the different homologs is needed to explain to what extent factors other than whole-grain rye and wheat affect the C17:0/C21:0 ratio. 35 The inverse association between C17:0/C21:0 and fasting insulin and insulin sensitivity indices observed in the present study is in line with previous findings showing positive effects of higher rye consumption on fasting plasma insulin and to a less extent on fasting plasma glucose 8 supporting the use of the ratio of the homologs C17:0 and C21:0 as an indicator of whole-grain/bran rye intake. It is, however, important to note that the AR C17:0/C21:0 ratio reflects only the relative whole-grain/bran rye consumption of total whole-grain wheat and rye intake, not total rye intake. In the present study the advised whole-grain rye intake was high in relation to other sources of AR and therefore the ratio should reflect the total rye intake reasonably well. Rye was mostly consumed in the form of bread.
Several intervention studies have shown diminished levels of postprandial insulin following a rye bread meal, [39] [40] [41] possibly explained by structural differences between rye and whole-wheat breads. 41, 42 The lower postprandial insulin response after rye bread consumption as compared with wheat bread may be due to the difference in structure rather than fiber content in the whole grain, as low-fiber rye bread showed the same results as high-fiber rye bread consumption. 43, 44 Moreover, an improved early insulin response has been shown after rye bread interventions. 43, 44 In the present study, there was, however, no significant association between the AR C17:0/C21:0 ratio and early or later insulin secretion phase as measured by insulin secretion indices.
One of the strengths of the present study is that AR is used as a dietary biomarker for whole-grain rye and wheat intake instead of self-reported estimates. Previously, we have demonstrated that AR is a good biomarker for the ND under intervention conditions with moderate-to-good reliability. 26 Also, reliable and comparable methods were used in six centers in four Nordic countries and the same study protocol was followed in all centers. However, it is important to note that AR is only a biomarker for whole-grain rye and wheat consumption, and therefore other markers are warranted in order to monitor whole-grain intake from other cereal sources.
CONCLUSION
The results support the use of the ratio of the homologs C17:0 and C21:0 as an indicator of rye intake in intervention studies where a diet rich in whole-grain rye is being investigated and also suggests that increased proportion of whole-grain rye in the diet may be associated with lower fasting insulin concentrations and increased insulin sensitivity. 
